Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|February 1, 2018
Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United StatesVictor W Sung, Ravi G Iyer, Sanjay K Gandhi, et al.
Journal of Health Economics and Outcomes Research|July 21, 2020
Retrospective Analysis of Healthcare Resource Use, Treatment Patterns, and Treatment-related Events in Patients with Huntington's Disease-associated Chorea Initiated on TetrabenazineVictor W Sung, Ravi G Iyer, Sanjay K Gandhi, et al.
Journal of Parkinson'S Disease|August 18, 2020
An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and DepressionDaryl DeKarske, Gustavo Alva, Jason L Aldred, et al.
The Patient|May 12, 2018
Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United StatesEileen Mack Thorley, Ravi G Iyer, Paul Wicks, et al.
Drug Safety|April 9, 2025
Evaluation of Mortality in Users of Pimavanserin Compared with Other Atypical Antipsychotics in Patients with Parkinson's Disease Psychosis: An UpdateSapna Rao, Lisa J McQuay, Joan Forns, et al.
Neurology|February 4, 2021
Association of Dementia-Related Psychosis With Long-term Care Use and DeathJames B Wetmore, Yi Peng, Heng Yan, et al.
Journal of Huntington'S Disease|June 9, 2020
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington DiseaseAndrew McGarry, Peggy Auinger, Karl Kieburtz, et al.
Parkinsonism & Related Disorders|May 2, 2021
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patientsStuart H Isaacson, Clive G Ballard, David L Kreitzman, et al.
Journal of Parkinson'S Disease|February 25, 2022
Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson's Disease (1991-2010)Cole D Stang, Aidan F Mullan, Emanuele Camerucci, et al.
Parkinsonism & Related Disorders|July 27, 2020
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosisClive G Ballard, David L Kreitzman, Stuart Isaacson, et al.
Pageof 5